Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics

Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years.

DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Adrenomyeloneuropathy Market Report:

The United States represented the largest share (around 45%) of the total AMN market among the 7MM (US, EU4, UK, and Japan) in 2024.
In December 2024, Bionomics Limited announced that positive Phase 2 ATTUNE trial results were published in NEJM Evidence and presented during the inaugural "Promising Targets" session at the 63rd Annual Meeting of the ACNP.
In October 2024, Spur Therapeutics published preclinical proof-of-concept data for SBT101, a first-in-class gene therapy for AMN, in Molecular Therapy Methods & Clinical Development, highlighting its potential as a breakthrough therapy.
In October 2024, Viking Therapeutics reported positive Phase Ib data for VK0214, supporting further development in AMN.
There were approximately 3,500 diagnosed prevalent cases of AMN in the 7MM in 2024, a number expected to grow by 2034.
In 2024, the total treated cases of Adrenomyeloneuropathy in Japan were around 433.
Among European countries, Germany had the highest diagnosed prevalence, followed by France, while Italy had the lowest number of cases.
Key Adrenomyeloneuropathy companies such as Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others are evaluating new drugs for Adrenomyeloneuropathy to improve the treatment landscape.

Adrenomyeloneuropathy Overview

Adrenomyeloneuropathy (AMN) is the most prevalent variant of adrenoleukodystrophy (ALD) and primarily affects adult males. The condition typically begins with a slow onset of symptoms, including leg stiffness, muscle weakness, walking difficulties, and nerve-related pain. As the disease advances, it often leads to bladder and bowel dysfunction as well as sexual dysfunction. Unlike the cerebral form of ALD, which causes rapid cognitive decline, AMN tends to progress more gradually and generally spares cognitive function, though it can still result in significant physical impairment over time.

Clinically, AMN is categorized into two subtypes:

AMN with cerebral involvement, where both the spinal cord and brain are affected.
AMN without cerebral involvement, where symptoms are limited to the spinal cord.
Approximately 54% of AMN patients maintain normal brain function, while 46% show some level of cerebral involvement. This classification is crucial for determining prognosis and tailoring treatment, as those with cerebral involvement often require more aggressive monitoring and intervention.

Adrenomyeloneuropathy Market Outlook

The **Adrenomyeloneuropathy (AMN) market** is slowly advancing, although the current development pipeline remains modest, especially considering the significant unmet needs of patients. Leading companies such as **Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics**, and others are actively progressing their core drug candidates through different clinical trial phases.

However, the market continues to face several challenges, including **limited disease awareness**, **reimbursement barriers**, and persistent concerns regarding the **effectiveness of existing treatment approaches**. Despite these obstacles, the AMN market is projected to grow in the coming years, fueled by a rising **prevalence of diagnosed cases**, **increased investment in research**, and ongoing innovation in therapeutic strategies. Additional growth is expected to come from **enhanced diagnostic capabilities**, **preventive healthcare initiatives**, and broader efforts to raise awareness and educate both patients and healthcare providers about the condition.

Discover how the Adrenomyeloneuropathy market is rising in the coming years @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adrenomyeloneuropathy Emerging Drugs
Leriglitazone (MIN-102): Minoryx Therapeutics
SBT101: Spur Therapeutics

Scope of the Adrenomyeloneuropathy Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Adrenomyeloneuropathy Companies: Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others
Adrenomyeloneuropathy Therapeutic Assessment: Adrenomyeloneuropathy current marketed and Adrenomyeloneuropathy emerging therapies
Adrenomyeloneuropathy Market Dynamics: Adrenomyeloneuropathy market drivers and Adrenomyeloneuropathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Adrenomyeloneuropathy Unmet Needs, KOL's views, Analyst's views, Adrenomyeloneuropathy Market Access and Reimbursement

To know what's more in our Adrenomyeloneuropathy report, visit https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Adrenomyeloneuropathy Market Report:
Adrenomyeloneuropathy market report covers a descriptive overview and comprehensive insight of the Adrenomyeloneuropathy Epidemiology and Adrenomyeloneuropathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Adrenomyeloneuropathy market report provides insights into the current and emerging therapies.
The Adrenomyeloneuropathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Adrenomyeloneuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Adrenomyeloneuropathy market.

Got queries? Click here to know more about the Adrenomyeloneuropathy market Landscape https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Adrenomyeloneuropathy Patient Share (%) Overview at a Glance
5. Adrenomyeloneuropathy Market Overview at a Glance
6. Adrenomyeloneuropathy Disease Background and Overview
7. Adrenomyeloneuropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Adrenomyeloneuropathy
9. Adrenomyeloneuropathy Current Treatment and Medical Practices
10. Unmet Needs
11. Adrenomyeloneuropathy Emerging Therapies
12. Adrenomyeloneuropathy Market Outlook
13. Country-Wise Adrenomyeloneuropathy Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Adrenomyeloneuropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Adrenomyeloneuropathy Market Outlook 2034 https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Adrenomyeloneuropathy Pipeline Insights, DelveInsight

"Adrenomyeloneuropathy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Adrenomyeloneuropathy market. A detailed picture of the Adrenomyeloneuropathy pipeline landscape is provided, which includes the disease overview and Adrenomyeloneuropathy treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.